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(6 ± 3.4 vs 5.3 ± 3.2), total inflation time (365 ± 202 vs 413 ± 197 sec) and
mean inflation pressure (5 ± 0.9 vs 5 ± 1 atm) was found between Gl and
G2 pts.
Conclusion: Our study shows that the plaque disruption and the brief pe-
riods of myocardial ischemia caused by PTCA elicit a variable individual in-
flammatory acute phase response, that is greater in UA compared to SA pts.
These data suggest a higher inflammatory responsiveness in patients with
UA, that may playa pathogenetic role in acute coronary syndromes, and
help explaining the higher rate of acute complications typically observed in
patients with unstable angina undergoing PTCA.
Thrombin receptor activating peptides have been shown to promote platelet
activation by binding to platelet thrombin receptors. Recently, thrombin re-
ceptors on the vessel wall have also been described but their role or func-
tion is unclear. Expression of thrombin receptors on the injured arterial wall
may be implicated in regUlating vessel wall thrombogenicity and influenc-
ing mural thrombus formation. To assess the role of thrombin receptors on
the thrombogenicity of the injured arterial wall, we examined the effect of
a putative thrombin-receptor antagonist (TRAN) on platelet and neutrophil
(PMN) deposition on porcine aortic media (simulating deeply injured arterial
wall). The aortic media exposed to increasing concentration of TRAN were
then placed in cylindrical flow chambers and exposed to circulating normal
~orcine blood at a shear rate of 3360 sec-1 for 5 min at 3rC. Ouantitative
1Cr platelet (x 106/cm2 ) and 11 Tin-neutrophil deposition (x 103 /cm 2 ) on
the aortic media at various concentrations of TRAN (10-8 to 10-6 M) (n = 6
in each case) are shown below:
ANOVA, • P < 0.05 vs control
Conclusion: Inhibition of the thrombin receptor on the arterial media sur-
face may inhibit the reactivity of the injured vessel wall to platelet and neu-
trophil accumulation. This may represent a novel mechanism of inhibiting
arterial thrombus formation, and decreasing the thrombogenicity and inflam-
matory response of the injured arterial wall.
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Thrombin Receptor Blockade on the Arterial Media
Decreases Its Reactivity to Platelets and Neutrophlls
Alvaro Moura, Jules Y.T. Lam, Glad Letchacovski, Morley Hollenberg, John Dimaio
Montreal Heart Institute, Montreal, Quebec, Canada
6.5 ± 1.5'
983 ± 389
NP
18 ± 032
420 ± 121
RecontrolISU
1.5 ± 1.17 4.6 ± 1.0'
447 ± 115 1276 ± 425'
Control
'p < 0.01 vs. Control or Recontrol
FBF (ml/100 gm/min)
NE slo (pg/min)
As expected, DMI reduced NE uptake activity in both SHAM and CHF ani-
mals, but its actions on TH differed between the two groups. While it exerted
no effect on TH in SHAM animals, DMI reduced the decrease in TH that oc-
curred in CHE The results suggest that the cardiac sympathetic changes that
occur in CHF may be caused by excessive NE, and that the neurotoxic effect
of NE on TH involves the NE reuptake mechanism.
Regional NE slo therefore increased after local infusion of isoproterenol,
but not after a similar increase in flow during nitroprusside. Although a flow-
dependent effect is not completely excluded, these data suggest that re-
gional beta adrenergic stimulation is capable of increasing local NE s/o. This
observation may be relevant to both the control of sympathetic activity and
the possible effects of beta blockers in CHE
Steven R. Goldsmith, Michael Garr Hennepin County Medical Center and the
University ofMinnesota, Minneapolis, MN
Beta blockers may be effective therapy in congestive heart failure; the rea-
sons are not fully clear. Presynaptic beta-l receptors are known to facilitate
norepinephrine (NE) release. If this effect occurs in congestive heart fail-
ure (CHF) an important positive feedback loop might exist contributing to
chronic sympathetic activation; conversely, interference with such an inter-
action could contribute to beneficial effects of beta adrenergic blockade. To
test the hypothesis that beta simulation would lead to increased local sympa-
thetic activity we measured regional forearm NE kinetics (clearance method
of Esler with 3HNE) during intraarterial infusion of subsystemic doses of iso-
proterenol (ISU) in 6 patients with chronic stable, moderate CHE As a control
for flow-related effects due to vasodilation from ISU, we also assessed the
response to nitroprusside (NP). Forearm blood flow (FBF) and regional NE
spillover (Regional NE slo = [NEa - NEvl + NEa [extraction 3HNE) x FBF)
were:
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Effect of Beta Adrenergic Stimulation on Regional
Norepinephrine Spillover In Human Congestive Heart
Failure
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Enhanced Inflammatory Acute Phase Response After
Percutaneous Coronary Angioplasty In Patients with
Unstable Angina
Giovanna Liuzzo, Antonino Buffon, Luigi M. Biasucci, Francesco De Felice,
Giuseppina Caligiuri, Rita L. Grillo, Gaetano Quaranta, Claudia Monaco,
Filippo Crea, Attilio Maseri. Cardiology, Catholic University, Rome, Italy
Elevated levels of C-reactive protein (CRP), a sensitive marker of inflamma-
tion, are independent predictors of short-term prognosis in patients (pts)
with unstable angina (UA). The causes of the acute phase response in UA,
however, are still unknown. Percutaneous transluminal coronary angioplasty
(PTCA) is an useful model for the assessment of the effects of plaque dis-
ruption and myocardial ischemia on the acute phase response. Serum levels
of CRP were measured in 21 pts with chronic stable angina (SA) (G 1) and
in 22 pts with UA refractory to maximal medical treatment (G2), undergoing
single-vessel PTCA. Venous blood samples were taken immediately before
PTCA and 6, 24, 48, 72 hours after the end of the procedure. CRP values are
expressed as median and range.
Results. Before PTCA, CRP was elevated (>3 mgll) in 2/21 G1 pts (10%)
and in 16/22 G2 pts (73%) (p < 0.001): it was 2.4 (2-4.4) mgll in Gl and 8
(2.4---29) mgll in G2 (p < 0.001). After PTCA, CRP increased to a peak value of
2.6 (2-16.4) mg/138 ± 13 hrs after the procedure in Gl, and to a peak value
of 19.9 (2.8-49.4) mgll 32 ± 14 hrs after the procedure in G2 (p < 0.001.
G1 vs G2). A significant increase in CRP after PTCA, defined as an increase
>50% the basal values, was observed in 8/21 Gl pts and in 16/22 G2 pts (p
< 0.05). The percentage increase of CRP after PTCA was higher in G2 than
in Gl (180 ± 239%, range 0-925% vs 118 ± 176%, range -13-489%, p <
0.05).
No difference in coronary stenosis severity before PTCA (84 ± 9% vs 89 ±
8%), residual stenosis (30 ± 7% vs 29 ± 10%). number of ballon inflations
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1810-31 Thrombin and Thromboxane A2 are both Important
Mediators of Thrombus Formation Under Flow
Conditions in Humans
Giovanni Melandri, Franco Semprini, Vittorio Cervi, Benedetta Descovich,
Stefano Boschi, Angelo Branzi, Bruno Magnani. Institute of Cardiology, University of
Bologna, Italy
Heparin (Hep) has been shown to be the first-line antithrombotic treatment in
unstable angina, thus confirming that thrombin is a potent mediator of throm-
bus formation on deep vascular injury. Whether aspirin treatment may further
add on the effects of heparin is controversial. To further elucidate the role of
thrombin and thromboxane A2 in this context, we investigated the effects of
Hep at low (0.2-0.4 U/ml; Hep-L) and high (0.5-1.0 U/ml; Hep-H) concentra-
tions and of Hep-L in presence of dual thromboxane inhibition/thromboxane
A2 receptor antagonism after the oral ingestion of Picotamide (pIC; 600 mg)
in humans. We used a flow system allowing for native human blood to be
exposed for 5 min to mild or deep vascular injury on porcine arterial seg-
ments. 11l-ln-labelled platelet deposition (PO x 106 I cm2) was quantified
on arterial segments in cylindrical (Badimon) flow chambers under low (212
s-l) and high (1690-1) shear rate at 37'C. PIC bioavailability was checked
by measuring thromboxane 82 synthesis by clotting human blood. Results
(SEM):
Hep-L Hep-H p Hep-L + PIC P
Mild injury (212 s-1J 1.6(0.4) 0.6(0.3) 07 (0.2)
Mild injury (1690 s-l) 3.9(1.0) 2.2(0.5) 1.8(004)
Deep injury (1690 s-1) 1204 (2.8) 8.2(2.0) 6.8 (104)
'p < 0.05, §p < 0.01 vs Hep-L
Thus, thrombin is a strong mediator of thrombosis under flow conditions
and requires high Hep levels. However a similar antithrombotic effect may
be achieved by the combination of thromboxane A2 blockade at the receptor
level with low Hep levels.
